Quest Diagnostics Inc. (DGX): Price and Financial Metrics

Quest Diagnostics Inc. (DGX): $135.43

0.51 (+0.38%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

DGX Price/Volume Stats

Current price $135.43 52-week high $158.34
Prev. close $134.92 52-week low $119.59
Day low $134.32 Volume 497,640
Day high $135.76 Avg. volume 975,214
50-day MA $129.45 Dividend yield 2.07%
200-day MA $134.36 Market Cap 15.23B

DGX Stock Price Chart Interactive Chart >

DGX POWR Grades

  • DGX scores best on the Quality dimension, with a Quality rank ahead of 82.21% of US stocks.
  • DGX's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • DGX's current lowest rank is in the Momentum metric (where it is better than 20.43% of US stocks).

DGX Stock Summary

  • QUEST DIAGNOSTICS INC's market capitalization of $15,310,273,541 is ahead of 87.42% of US-listed equities.
  • As for revenue growth, note that DGX's revenue has grown -9.69% over the past 12 months; that beats the revenue growth of merely 22.91% of US companies in our set.
  • In terms of volatility of its share price, DGX is more volatile than only 4.69% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to QUEST DIAGNOSTICS INC, a group of peers worth examining would be PKG, COTY, BEN, BRO, and RS.
  • Visit DGX's SEC page to see the company's official filings. To visit the company's web site, go to www.questdiagnostics.com.

DGX Valuation Summary

  • In comparison to the median Healthcare stock, DGX's price/earnings ratio is 25.05% lower, now standing at 19.9.
  • DGX's price/earnings ratio has moved up 1.5 over the prior 243 months.

Below are key valuation metrics over time for DGX.

Stock Date P/S P/B P/E EV/EBIT
DGX 2023-11-20 1.6 2.4 19.9 17.9
DGX 2023-11-17 1.6 2.4 19.9 17.9
DGX 2023-11-16 1.6 2.4 19.9 17.9
DGX 2023-11-15 1.6 2.4 20.0 18.0
DGX 2023-11-14 1.6 2.3 19.7 17.8
DGX 2023-11-13 1.6 2.3 19.5 17.7

DGX Growth Metrics

    Its 2 year revenue growth rate is now at 39.47%.
  • Its year over year net cashflow from operations growth rate is now at -20.37%.
  • Its 3 year revenue growth rate is now at 41.67%.
Over the past 34 months, DGX's revenue has gone up $2,226,000,000.

The table below shows DGX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 9,883 1,718 946
2022-09-30 10,294 1,865 1,235
2022-06-30 10,582 1,924 1,484
2022-03-31 10,679 1,982 1,881
2021-12-31 10,788 2,233 1,995
2021-09-30 11,046 2,293 2,184

DGX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DGX has a Quality Grade of B, ranking ahead of 93.32% of graded US stocks.
  • DGX's asset turnover comes in at 0.812 -- ranking 31st of 81 Healthcare stocks.
  • SSY, LH, and BIOC are the stocks whose asset turnover ratios are most correlated with DGX.

The table below shows DGX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.812 0.403 0.404
2021-06-30 0.805 0.412 0.417
2021-03-31 0.750 0.404 0.340
2020-12-31 0.709 0.385 0.277
2020-09-30 0.643 0.362 0.221
2020-06-30 0.604 0.334 0.162

DGX Price Target

For more insight on analysts targets of DGX, see our DGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $157.67 Average Broker Recommendation 1.56 (Moderate Buy)

Quest Diagnostics Inc. (DGX) Company Bio


Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United StatesPuerto RicoMexico, and Brazil.  Quest also maintains collaborative agreements with various hospitals and clinics across the globe. (Source:Wikipedia)


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.

What’s Ahead for Data

This special report explores where data science is headed, from efforts to speed diagnosis and treatment of disease to wearable computers that will read your brain waves—and enhance your performance

Yahoo | December 1, 2023

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.

Yahoo | November 30, 2023

Quest Diagnostics' (DGX) New Pact to Scale Precision Medicine

Quest Diagnostics' (DGX) will supply next-generation sequencing and enhanced RNA extraction services for Scipher's PrismRA test through a new collaboration.

Yahoo | November 29, 2023

Quest Volunteers Bring Treats, No Tricks, to Ronald McDonald House New York

NORTHAMPTON, MA / ACCESSWIRE / November 28, 2023 / Quest volunteers recently served lunch to children and families battling pediatric cancer and other serious illnesses at Ronald McDonald House New York, in collaboration with Quest for Health Equity ...

Yahoo | November 28, 2023

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Scipher Medicine, a precision immunology company, today announced a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).

Yahoo | November 28, 2023

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 1.92%
3-mo 7.24%
6-mo 1.76%
1-year -7.24%
3-year 16.80%
5-year 71.40%
YTD -11.65%
2022 -7.80%
2021 47.86%
2020 14.11%
2019 31.13%
2018 -13.84%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!